Wall Street Journal reporter David Wainer spotlights a 2021 study conducted Prof. Andrew Lo and his colleagues that investigated “what happened to innovation when drug companies were no longer able to resort to one of their favorite tactics: paying generic makers to stay off the market.”
Jamie Karraker BS ’12 MS ’13 co-founded Alto Pharmacy – a full-service, online pharmacy that aims to create a transparent, straightforward and user-friendly experience, reports Erika Fry for Fortune. “All patients need to do after seeing their doctor is interface with the app (or via text) and pick up the prescription from their front door,” writes Fry.
Landmark Bio, a cell and gene therapy manufacturing company co-founded by MIT and a number of other institutions, is focused on accelerating access to innovative therapies for patients, reports Rowan Walrath for Boston Business Journal. "Landmark's new facility includes laboratory space for research and early-stage drug development, as well as analytics tools,” writes Walrath.
MIT and a number of other local institutions have launched Landmark Bio, a cell and gene therapy manufacturing firm aimed at helping small startups develop experimental therapies that are reliable, consistent, and large enough to be used in clinical trials, reports Ryan Cross for The Boston Globe.
TechCrunch reporter Devin Coldewey spotlights how MIT researchers have developed a machine learning technique for proposing new molecules for drug discovery that ensures suggested molecules can be synthesized in a lab. Coldewey also features how MIT scientists created a new method aimed at teaching robots how to interact with everyday objects.
MIT researchers have developed a new technique that uses deep learning to improve the process of drug discovery, reports Jonathan Vanian for Fortune. “The technique addresses a common problem that researchers face when using A.I. to develop novel molecular structures: life sciences experts can often face challenges synthesizing A.I.-created molecular structures,” writes Vanian.
Writing for The New York Times, Prof. Amy Finkelstein explores the need to reign in prices of drugs administered by physicians. “Economists tend to favor letting the private sector set prices, but this requires a well-functioning market,” writes Finkelstein. “In trying to base its payments on what other customers pay, Medicare has distorted the market for physician-administered drugs beyond reason.”
Writing for The New York Times, visiting scientist Mark Trusheim and Peter Bach of Memorial Sloan Kettering Cancer Center explore how to lower the cost of biologic drugs. “Prices of new drugs will continue to make headlines, as well they should,” they write. “But we must fix the problem that older biologic drugs have perpetually high prices, and do so by passing a law that ensures that at the appropriate time their prices fall fast, and they fall far.”
CNBC reporter Charlie Wood features tProf. Connor Coley's work developing a new system that could be used to help automate molecule manufacturing. “It tries to understand, based on those patterns, what kind of transformations should work for new molecules it’s never seen before,” says Coley.
The Association for the Advancement of Artificial Intelligence has awarded Prof. Regina Barzilay a $1 million prize for her work advancing the use of AI in medicine, reports John McCormick for The Wall Street Journal. "Regina is brilliant, has very high standards, and is committed to helping others,” says Prof. James Collins. “And I think her experience with—her personal experience with cancer—has motivated her to apply her intellectual talents to using AI to advance health care.”
The AP highlights how Prof. Regina Barzilay has been named the inaugural winner of a new award given by the Association for the Advancement of Artificial Intelligence for her work “using computer science to detect cancer and discover new drugs has won a new $1 million award for artificial intelligence.”
Prof. Regina Barzilay has been named the inaugural recipient of the Squirrel AI Award for Artificial Intelligence to Benefit Humanity for her work developing new AI techniques to help improve health care, reports Rebecca Robbins for STAT. Robbins writes that Barzilay is focused on turning the “abundance of research on AI in health care into tools that can improve care.”
STAT reporter Kate Sheridan spotlights MIT startup Lyra Therapeutics, which is developing a long-acting treatment for chronic rhinosinusitis.
Writing for Science, Derek Lowe spotlights how MIT researchers are developing a platform that could be used to automate the production of molecules for use in medicine, solar energy and more. “The eventual hope is to unite the software and the hardware in this area,” reports Lowe, “and come up with a system that can produce new compounds with a minimum of human intervention.”
MIT researchers have found that some inactive ingredients in medications could play a role in triggering irritation or allergic reactions, reports Bob McDonald for CBC Radio. The researchers hope that, “pharmaceutical companies provide more information to doctors, and that alternative drug formulas can be developed for people with allergies or sensitivities.”